Sign up for our Oncology Central weekly news round-up

Top 3 cancer drug approvals: January 2022

Written by Jade Parker, Senior Editor

cancer drug approvals

To hail in the start of the new year we are highlighting three cancer drug approvals that have occurred over the past month. Read on to find out what advancements have been made in treatment options for NSCLC both in China and the UK, as well as a US FDA drug approval for melanoma. Tagrisso® (osimertinib) Approved: 6 January 2022 Approving body: China National Medical Products Administration (CNMP) Indication: Locally advanced or metastatic NSCLC At the start of January we saw the first drug approval for NSCLC in 2022. The CNMP approved BeiGene’s (Beijing, China) anti-PD-1 antibody tislelizumab as a...

To view this content, please register now for access

It's completely free